Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
New Applications in the Diagnosis and Therapy of Diseases, 2nd...
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

New Applications in the Diagnosis and Therapy of Diseases, 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 March 2025 | Viewed by 2536

Special Issue Editors

Dr. Miguel Hueso

E-Mail Website
Guest Editor
Department of Nephrology, Hospital Universitari de Bellvitge, 08907 L’Hospitalet de Llobregat, Spain
Interests: kidney pathology; dialysis; vascular pathology; molecular medicine; predictive medicine; personalized medicine; inflammation; ncRNAs; organs-on-chip; artificial intelligence
Special Issues, Collections and Topics in MDPI journals
Dr. Alfredo Vellido

E-Mail Website
Guest Editor
IDEAI_UPC Research Center, Universitat Politècnica de Catalunya (UPC BarcelonaTech), 08034 Barcelona, Spain
Interests: machine learning; data science; medical applications of artificial intelligence
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Personalized medicine is an emerging field that promotes the use of novel diagnostic tests to offer the right treatment at the right time for each patient. Personalized medicine unavoidably leads us towards a data-centric view of health, as data from expensive multicenter, randomized, controlled clinical trials (evidence-based medicine) are required to demonstrate that a treatment is effective, but the results can be disappointing in population minorities. Therefore, an analysis of retrospective data collected in large databases (Big Data) can help to explore usefulness in population minorities and benefit patients and health systems. However, data must usually be obtained from heterogeneous sources and in different modalities (individual medical history, high-resolution images, omics data, diagnostic tests, etc.) and their analysis may become complex due to non-linear behaviour or changing dynamics. Therefore, modelling such complexity is a major challenge that requires powerful new tools and technologies. This is a natural challenge and pursuit for data science in the form of data collection, storage, curation of databases, processing, and analysis. We argue that the knowledge generated by data science approaches will have a positive impact on clinical practice through personalized treatments, and we would like to dedicate a Special Issue to collecting experiences of the diagnosis and personalized treatment of diseases from a data science and molecular perspective. Review papers and work in progress putting forward new and groundbreaking ideas are also welcomed.

Dr. Miguel Hueso
Dr. Alfredo Vellido
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized medicine
  • systems biology
  • high-throughput technologies
  • molecular imaging
  • omics
  • pharmacogenomics
  • monitoring responses
  • data visualization
  • theranostics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 2871 KiB  
Article
Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target
by Kentaro Hisada, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, Atsuko Saito, Tadashi Watabe, Sifan Feng, Kazuhiro Ooe, Xiaojie Yin, Hiromitsu Haba, Masashi Murakami, Atsushi Toyoshima, Jens Cardinale, Frederik L. Giesel and Koichi Fukase
Int. J. Mol. Sci. 2024, 25(22), 12296; https://doi.org/10.3390/ijms252212296 - 15 Nov 2024
Viewed by 664
Abstract
Novel nuclear medicine therapeutics are being developed by labeling medium-molecular-weight compounds with short-lived alpha-emitting radionuclides. Fibroblast activation protein α (FAPα) is recognized as a highly useful molecular target, and its inhibitor, FAPI, is a compound capable of theranostics, both therapeutic and diagnostic, [...] Read more.
Novel nuclear medicine therapeutics are being developed by labeling medium-molecular-weight compounds with short-lived alpha-emitting radionuclides. Fibroblast activation protein α (FAPα) is recognized as a highly useful molecular target, and its inhibitor, FAPI, is a compound capable of theranostics, both therapeutic and diagnostic, for cancer treatment. In this study, we compared the functions of two compounds that target FAPα: 211At-FAPI1 and 211At-FAPI2. First, in vitro screening procedures are generally accepted because of the low endogenous expression of FAPα. We suggest the usefulness of this 3D culture system for in vitro screening. Second, when FAPIs are used therapeutically, the expected therapeutic effects are often not achieved. Therefore, we compared the accumulation and excretion in tumor tissues and the anti-tumor effects based on the length of the linker in the compounds. The compounds were rapidly labeled using the Shirakami reaction. Doubling the linker length increased tumor retention. Additionally, the excretion pathway was altered, suggesting a potential reduction in toxicity. Although no significant differences were observed in the anti-tumor effects of 211At-FAPI1 and 211At-FAPI2, it was confirmed that the linker length affects the biological half-life. Full article
(This article belongs to the Special Issue New Applications in the Diagnosis and Therapy of Diseases, 2nd Edition)
►▼ Show Figures

Figure 1

33 pages, 13307 KiB  
Article
A Study on the Robustness and Stability of Explainable Deep Learning in an Imbalanced Setting: The Exploration of the Conformational Space of G Protein-Coupled Receptors
by Mario A. Gutiérrez-Mondragón, Alfredo Vellido and Caroline König
Int. J. Mol. Sci. 2024, 25(12), 6572; https://doi.org/10.3390/ijms25126572 - 14 Jun 2024
Viewed by 1056
Abstract
G-protein coupled receptors (GPCRs) are transmembrane proteins that transmit signals from the extracellular environment to the inside of the cells. Their ability to adopt various conformational states, which influence their function, makes them crucial in pharmacoproteomic studies. While many drugs target specific GPCR [...] Read more.
G-protein coupled receptors (GPCRs) are transmembrane proteins that transmit signals from the extracellular environment to the inside of the cells. Their ability to adopt various conformational states, which influence their function, makes them crucial in pharmacoproteomic studies. While many drugs target specific GPCR states to exert their effects—thereby regulating the protein’s activity—unraveling the activation pathway remains challenging due to the multitude of intermediate transformations occurring throughout this process, and intrinsically influencing the dynamics of the receptors. In this context, computational modeling, particularly molecular dynamics (MD) simulations, may offer valuable insights into the dynamics and energetics of GPCR transformations, especially when combined with machine learning (ML) methods and techniques for achieving model interpretability for knowledge generation. The current study builds upon previous work in which the layer relevance propagation (LRP) technique was employed to interpret the predictions in a multi-class classification problem concerning the conformational states of the β2-adrenergic (β2AR) receptor from MD simulations. Here, we address the challenges posed by class imbalance and extend previous analyses by evaluating the robustness and stability of deep learning (DL)-based predictions under different imbalance mitigation techniques. By meticulously evaluating explainability and imbalance strategies, we aim to produce reliable and robust insights. Full article
(This article belongs to the Special Issue New Applications in the Diagnosis and Therapy of Diseases, 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

19 pages, 1408 KiB  
Review
Angiopoietin-2: A Therapeutic Target for Vascular Protection in Hutchinson–Gilford Progeria Syndrome
by Sahar Vakili and Kan Cao
Int. J. Mol. Sci. 2024, 25(24), 13537; https://doi.org/10.3390/ijms252413537 - 18 Dec 2024
Viewed by 223
Abstract
Hutchinson–Gilford progeria syndrome (HGPS) is a pediatric condition characterized by clinical features that resemble accelerated aging. The abnormal accumulation of a toxic form of the lamin A protein known as progerin disrupts cellular functions, leading to various complications, including growth retardation, loss of [...] Read more.
Hutchinson–Gilford progeria syndrome (HGPS) is a pediatric condition characterized by clinical features that resemble accelerated aging. The abnormal accumulation of a toxic form of the lamin A protein known as progerin disrupts cellular functions, leading to various complications, including growth retardation, loss of subcutaneous fat, abnormal skin, alopecia, osteoporosis, and progressive joint contractures. Death primarily occurs as the result of complications from progressive atherosclerosis, especially from cardiac disease, such as myocardial infarction or heart failure, or cerebrovascular disease like stroke. Despite the availability of lonafarnib, the only US Food and Drug Administration-approved treatment for HGPS, cardiovascular complications remain the leading cause of morbidity and mortality in affected patients. Defective angiogenesis—the process of forming new blood vessels from existing ones—plays a crucial role in the development of cardiovascular disease. A recent study suggests that Angiopoietin-2 (Ang2), a pro-angiogenic growth factor that regulates angiogenesis and vascular stability, may offer therapeutic potential for the treatment of HGPS. In this review, we describe the clinical features and key cellular processes impacted by progerin and discuss the therapeutic potential of Ang2 in addressing these challenges. Full article
(This article belongs to the Special Issue New Applications in the Diagnosis and Therapy of Diseases, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop